The short version of N-terminal modification fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-11. Anything still debated is marked as such rather than presented as settled.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 可能具吸湿性 |
| 溶解性 | 溶于水和水性缓冲液 | 典型肽类行为 |
| 冻干粉储存 | -20°C 或 2-8°C，避光 | 长期稳定性较好 |
| 复溶后储存 | 2-8°C，短期 | 避免反复冻融 |
| 常用分析 | RP-HPLC 与 LC-MS | 纯度与身份确认 |
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
=== Government efficiency === In 1997, Rolling Stone published a comprehensive snapshot of the US government's implementation of the war on drugs, spanning 44 federal agencies and hundreds of thousands of government workers, and without unified management, oversight, or cohesive strategy. Among the agencies there were over a dozen separate drug intelligence operations. The White House's Office of National Drug Control Policy, home of the drug czar and ostensibly the coordinating agency, had a staff of 150, and a $36 million budget; the overall federal drug war budget for 1998 was $16 billion. Most of the agencies involved did not report to the ONDCP, instead to one of 13 congressional appropriations subcommittees. The largest single share of the budget, $2 billion, went to the Bureau of Prisons. Federal agencies also passed on billions of anti-drug dollars to the states, with little oversight or accountability. In 2024, the ONDCP requested $461 million of a $46 billion federal budget allocated across some 50 federal agencies.
=== Thyroid cancer === The US Food and Drug Administration requires a boxed warning in the package inserts of GLP-1 agonists due to the risk of thyroid C-cell tumors, including medullary thyroid cancer (MTC). GLP-1 agonists are contraindicated in people with a family or personal history of MTC or multiple endocrine neoplasia type 2. In mice, long-term use of GLP-1 agonists stimulates calcitonin secretion, leading to C-cell hypertrophy and increased risk of thyroid cancer, but no increased secretion of calcitonin has been observed in humans. A retrospective national cohort study in France reported an increased risk of thyroid cancer (all and medullary) after 1–3 years of treatment with GLP-1 agonists for diabetes, but other large retrospective studies have not reported a similar association, including with long-term use of GLP-1 agonists and over 10 years of followup.
Due to the neurotoxicity of its metabolite, norpethidine, it is more toxic than other opioids—especially during long-term use. The norpethidine metabolite was found to have serotonergic effects, so pethidine could, unlike most opioids, increase the risk of triggering serotonin syndrome.
Sources: en.wikipedia.org
Direct skin contact with nickel-releasing item Prolonged skin contact with nickel-releasing item A sufficient amount of nickel is released and absorbed into the skin to cause a reaction The pathophysiology is divided into induction elicitation phases. Induction is the critical phase (immunological event) when skin contact to nickel results in antigen presentation to the T cells, and T cell duplication (cloning) occurs. The metal cation Ni++ is a low molecular weight hapten that easily penetrates the stratum corneum (top layer of skin). Nickel then binds to skin protein carriers creating an antigenic epitope. The determining factor in sensitization is exposure of significant amounts of "free nickel". This is important because different metal alloys release different amounts of free nickel. The antigenic epitope is collected by dermal dendritic cells and Langerhans cells, the antigen-presenting cells (APC) of the skin, and undergo maturation and migration to regional lymph nodes. The complex is predominantly expressed on major histocompatibility complex (MHC) II, which activates and clonally expands naive CD4+ T cells. Upon re-exposure these now primed T cells will be activated and massively recruited to the skin, resulting in the elicitation phase and the clinical presentation of Ni-ACD. Although ACD has been considered a Th1 predominate process, recent studies highlight a more complex picture. In Ni-ACD other cells are involved including: Th17, Th22, Th1/IFN and the innate immune responses consistent with toll-like receptor 4.
== Fusion in eukaryotes == Eukaryotic genomes contain several gene families, of host and viral origin, which encode products involved in driving membrane fusion. While adult somatic cells do not typically undergo membrane fusion under normal conditions, gametes and embryonic cells follow developmental pathways to non-spontaneously drive membrane fusion, such as in placental formation, syncytiotrophoblast formation, and neurodevelopment. Fusion pathways are also involved in the development of musculoskeletal and nervous system tissues. Vesicle fusion events involved in neurotransmitter trafficking also relies on the catalytic activity of fusion proteins.
The role of NE in schizophrenia has not been fully understood, but has stimulated research into this topic. The only relationship that has been understood between researchers is that there is a positive correlation between increased NE levels in the brain and spinal fluid (CSF) and activity of schizophrenia. In one study, clonidine, a drug used to treat medical conditions such as ADHD and high blood pressure, was shown to produce a significant decrease in plasma level MHPG (3-methoxy-4-hydroxyphenylglycol), a metabolite of NE, in the normal control group, but not in the group of schizophrenic patients. This suggests that in schizophrenia, the alpha-2 adrenergic receptor, a presynaptic inhibitory receptor, may be less sensitive compared to normally functioning alpha-2 receptors and thus relate to elevated NE levels in the disorder. In addition to increased NE levels in the brain and CSF, increased levels of MHPG has also been associated with a diagnosis of schizophrenia. Impaired NE regulation in schizophrenia has been an area of interest for researchers and research on this topic is still ongoing.
However, Watson and Crick found fault in her steadfast assertion that, according to her data, a helical structure was not the only possible shape for DNA—so they had a dilemma. In an effort to clarify this issue, Max Ferdinand Perutz later published what had been in the progress report, and suggested that nothing was in the report that Franklin herself had not said in her talk (attended by Watson) in late 1951. Perutz explained that the report was to a Medical Research Council (MRC) committee that had been created to "establish contact between the different groups of people working for the Council". Randall's and Perutz's laboratories were both funded by the MRC. It is also not clear how important Franklin's unpublished results from the progress report actually were for the model-building done by Watson and Crick. After the first crude X-ray diffraction images of DNA were collected in the 1930s, William Astbury had talked about stacks of nucleotides spaced at 3.4 angström (0.34 nanometre) intervals in DNA. A citation to Astbury's earlier X-ray diffraction work was one of only eight references in Franklin's first paper on DNA. Analysis of Astbury's published DNA results and the better X-ray diffraction images collected by Wilkins and Franklin revealed the helical nature of DNA. It was possible to predict the number of bases stacked within a single turn of the DNA helix (10 per turn; a full turn of the helix is 27 angströms [2.7 nm] in the compact A form, 34 angströms [3.4 nm] in the wetter B form).
Sources: en.wikipedia.org
A critical feature of portals is that they retain the speed of the object traveling through it. When portals are placed on non-parallel planes, this can create the effect of "flinging". The player often uses gravity to build up their momentum when they fall into a portal, which flings them out of the other side to gain speed and distance that normal jumping and running could not generate. A leapfrogging effect can be used by placing portals in series during this flinging, gaining further momentum with each use. Portals will also allow light and other objects to transfer through them, and numerous puzzles involve using portals to manipulate bouncing energy balls, lasers, "hard light" bridges, and tractor beams to access new locations or direct objects to specific receptacles that must be activated to open the level's exit. Portal 2 introduces "mobility gels" that can paint surfaces, including turrets and cubes, that can also move through portals though not directly by the player. The gels can create a surface that repels the player (Repulsion Gel), increases the player's speed (Propulsion Gel), or allows the surface to accept portals (Conversion Gel). The games' credit sequences feature the songs "Still Alive" and "Want You Gone" composed by Jonathan Coulton, and, in its original form, sung by Ellen McLain in the GLaDOS voice. Portal 2 also features the song "Exile Vilify" by The National.
== Medical uses == In the European Union, insulin efsitora alfa is indicated for the treatment of type 2 diabetes in adults. In the United States, insulin efsitora alfa indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
== Impact of narcotics trafficking == In the late 1980s, there continued to be concern about an overburdened and allegedly corrupt judicial system. According to the Department of State's Country Reports on Human Rights Practices for 1988 and Bolivian press reports, judges were implicated in drug-related corruption. Narcotics traffickers routinely tried to bribe judicial and other officials in exchange for releasing suspected smugglers, returning captured drugs, and purging incriminating files. In 1988 the Senate's Constitution and Justice Committee ordered the suspension of thirteen judges of the La Paz, Cochabamba, and Santa Cruz superior district courts of justice for wrongdoing in drug-trafficking cases. The Supreme Court of Justice insisted, however, on its prerogative to try the judges first. After doing so, it ordered the suspension of several of the accused judges and continued to investigate others. Relatively few prosecutions or forfeitures of traffickers' assets took place. A lack of judicial investigatory power hampered the investigation of the bank accounts and the origin of wealth of people suspected of trafficking in drugs. Although thirteen of the "big bosses" reportedly had been identified by early 1988, arrests of drug kingpins were infrequently reported because of lack of evidence.
James L. Winkle College of Pharmacy Linder College of Business - Masters in Business Administration College of Allied Health - Masters in Health Administration The programs are organized as preparation for leadership in settings such as independent and chain community pharmacies, health-system inpatient, outpatient and clinical pharmacies, clinical coordinator roles, managed care, industry, long-term care.
HCTU is an amidinium coupling reagent used in peptide synthesis. It is analogous to HBTU. The HOBt moiety has a chlorine in the 6 position which improves reaction rates and the synthesis of difficult couplings HCTU and related reagents containing the 6-chloro-1-hydroxybenzotriazole moiety can be prepared by reaction with TCFH under basic conditions. It can exist in an N-form (guanidinium) or an O-form (uronium), but the N-form is generally considered to be more stable for this class of reagent. In vivo dermal sensitization studies according to OECD 429 confirmed HCTU is a strong skin sensitizer, showing a response at 0.50 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A.
Sources: en.wikipedia.org
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。
高温、强光、潮湿和反复冻融都会加速肽降解。冻干粉通常建议低温避光保存。复溶后的溶液稳定性较短，应依据验证数据确定保存条件。
氧化、脱酰胺和截短肽可能影响色谱纯度和生物活性读数。不同批次之间这些杂质的相对比例可能不同。是否具有临床意义取决于杂质水平、给药途径和暴露量，尚无统一阈值。
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.